NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** Brazil **If applicable, name of local government involved (Article 3.2 and 7.2):**  |
| **2.** | **Agency responsible:** National Institute of Metrology, Quality and Technology (INMETRO)Telephone: +(55) 21 2563.2918Telefax: +(55) 21 2563.5637Email: barreirastecnicas@inmetro.gov.br Web-site: [www.inmetro.gov.br/barreirastecnicas](http://www.inmetro.gov.br/barreirastecnicas) **Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:** Brazilian Health Regulatory Agency (ANVISA) |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****],** **other****:**  |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** HS Code(s): 3006 (OTC medicines) |
| **5.** | **Title, number of pages and language(s) of the notified document:** Draft normative instruction number 726, 18 September 2019. (38 page(s), in Portuguese)Comment form: http://formsus.datasus.gov.br/site/formulario.php?id\_aplicacao=50605  |
| **6.** | **Description of content:** This draft normative instruction establishes the list of medicines defined by Anvisa as exempt from prescription, in the form of Lists of over-the-counter medicines (OTC) for biological and synthetic or herbal medicines, annexes I and II of this Normative Instruction, respectively, in attendance with the Resolution – RDC number 98, 1 August 2016. |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** Protection of human health |
| **8.** | **Relevant documents:** * [Resolution - RDC number 98, 1 August 2016](http://portal.anvisa.gov.br/documents/10181/2921766/RDC_98_2016.pdf/32ea4e54-c0ab-459d-903d-8f8a88192412)
 |
| **9.** | **Proposed date of adoption:** To be determined after the end of the consultation period.**Proposed date of entry into force:** In the date of its publication. |
| **10.** | **Final date for comments:** 18 November 2019 |
| **11.** | **Texts available from: National enquiry point [****X]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:** Brazilian Health Regulatory Agency (Anvisa)SIA, Trecho 5, Área Especial 57Brasília – DF/BrazilCEP: 71.205-050Phone.: +(55) 61 3462.5402Website: [www.anvisa.gov.br](http://www.anvisa.gov.br)[http://portal.anvisa.gov.br/documents/10181/5600976/SEI\_ANVISA+-+0741308+-+Consulta+P%C3%BAblica+N%C2%B0+726.pdf/3afd30ae-8348-4c5e-81d0-c69799fef26a](http://portal.anvisa.gov.br/documents/10181/5600976/SEI_ANVISA%2B-%2B0741308%2B-%2BConsulta%2BP%C3%BAblica%2BN%C2%B0%2B726.pdf/3afd30ae-8348-4c5e-81d0-c69799fef26a) |